Citations

Mayo Clinic

Showing 10 of 108602 citations.

What do patients think about palliative care? A national survey of hematopoietic stem cell transplant recipients
Barata, Anna , Abrams, Hannah R. , Meyer, Christa L. , Mau, Lih‐Wen, Mattila, Deborah, Burns, Linda J. , Ullrich, Christina , Wood, William A. , Petersdorf, Effie W. , LeBlanc, Thomas W. , El‐Jawahri, Areej , Meyer, Christa , Leblanc, Thomas , Wood, William A , Murthy, Hemant S.

Blood Advances | March 6, 2023 | Volume: 7 | Issue: 10 | Pages: 2032-2041

10.1182/bloodadvances.2023009712 | PMID 36877661 Get It

Abstract Palliative care (PC) benefits patients undergoing hematopoietic stem cell transplantation (HSCT), but it remains underutilized. Although transplant physicians report concerns regarding how patients perceive PC, HSCT recipients’ perceptions about PC remain unaddressed. We conducted a multisite, cross-sectional survey of autologous and allogeneic HSCT recipients 3 to 12 months after transplant to assess their familiarity, knowledge, and perception of PC, as well as their unmet PC needs. We computed a composite score of patients’ perceptions of PC and used a generalized linear regression model to examine factors associated with these perceptions. We enrolled 69.6% (250/359) of potential participants (median age = 58.1; 63.1% autologous HSCT). Overall, 44.3.8% (109/249) reported limited knowledge about PC and 52% (127/245) endorsed familiarity with PC. Most patients felt hopeful (54%) and reassured (50%) when they heard the term PC; 83% saw referral as a sign their doctor cared about what was happening to them. In multivariate analyses, patients who were more knowledgeable about PC were more likely to have positive perceptions of PC (B = 7.54, standard error = 1.61, P < .001). Patients’ demographics, HSCT features, quality of life, and symptom burden were not significantly associated with perceptions of PC. HSCT recipients have positive perceptions of PC, though many have limited knowledge about its role. Patients who were more knowledgeable about PC were more likely to have positive perceptions of PC. These data do not support transplant physicians’ negative concerns about how patients perceive PC and underscore the need to further educate patients and transplant physicians about PC.
International Consensus Statement on the Radiological Screening of Contact Children in the Context of Suspected Child Physical Abuse
Mankad, Kshitij , Sidpra, Jai , Oates, Adam , Kan, Elaine , Agrawal, Nina, Kelly, Patrick J. , Zeitlin, Deborah, Carter, Jamieson, Debelle, Geoff , Berger, Rachel P. , Christian, Cindy W. , Lindberg, Daniel M. , Raissaki, Maria , Argyropoulou, Maria I. , Adamsbaum, C. , Cain, Timothy , Silvera, V. Michelle , Kemp, Alison , Choudhary, Arabinda K. , Offiah, Amaka C , Mirsky, David M. , Colleran, Gabrielle , Lucato, Leandro Tavares , Kilborn, Tracy , Teeuw, Arianne Hélène , Zeitlin, Deborah, Carter, Jamieson, Rijn, Rick Robert van , Rossi, Andrea

JAMA Pediatrics | March 6, 2023 | Volume: 177 | Issue: 5 | Pages: 526

10.1001/jamapediatrics.2022.6184 | PMID 36877504 Get It

Importance Physical abuse is a common but preventable cause of long-term childhood morbidity and mortality. Despite the strong association between abuse in an index child and abuse in contact children, there is no guidance outlining how to screen the latter, significantly more vulnerable group, for abusive injuries. Consequently, the radiological assessment of contact children is often omitted, or variably performed, allowing occult injuries to go undetected and increasing the risk of further abuse. Objective To report an evidence-based and consensus-derived set of best practices for the radiological screening of contact children in the context of suspected child physical abuse. Evidence Review This consensus statement is supported by a systematic review of the literature and the clinical opinion of an internationally recognized group of 26 experts. The modified Delphi consensus process comprised 3 meetings of the International Consensus Group on Contact Screening in Suspected Child Physical Abuse held between February and June 2021. Findings Contacts are defined as the asymptomatic siblings, cohabiting children, or children under the same care as an index child with suspected child physical abuse. All contact children should undergo a thorough physical examination and a history elicited prior to imaging. Contact children younger than 12 months should have neuroimaging, the preferred modality for which is magnetic resonance imaging, and skeletal survey. Contact children aged 12 to 24 months should undergo skeletal survey. No routine imaging is indicated in asymptomatic children older than 24 months. Follow-up skeletal survey with limited views should be performed if abnormal or equivocal at presentation. Contacts with positive findings should be investigated as an index child. Conclusions and Relevance This Special Communication reports consensus recommendations for the radiological screening of contact children in the context of suspected child physical abuse, establishing a recognized baseline for the stringent evaluation of these at-risk children and providing clinicians with a more resilient platform from which to advocate for them.
Author response: Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study
Luckett, Patrick H. , Fagan, Anne M. , Perrin, Richard J. , Farlow, Martin R. , Mori, Hiroshi , Nübling, Georg, Network, The Dominantly Inherited Alzheimer, Millar, Peter R , Gordon, Brian A. , Benzinger, Tammie L.S. , Cruchaga, Carlos , Hassenstab, Jason , Schindler, Suzanne E. , Allegri, Ricardo , Day, Gregory S. , Nübling, Georg , Network, The Dominantly Inherited Alzheimer, Bateman, Randall J. , Morris, John C. , Ances, Beau M.

No container title available | March 6, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.81869.sa2 Get It

Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial
Haines, David E. , Boersma, Lucas V.A. , Sood, Nitesh , Natale, Andrea , Marchlinski, Francis E. , Calkins, Hugh , Sanders, Prashanthan , Packer, Douglas L. , Kuck, Karl-Heinz , Hindricks, Gerhard , Önal, Birce , Cerkvenik, Jeffrey , Tada, Hiroshi , Investigators, on behalf of the PULSED AF, Verma, Atul , Boersma, Lucas , Natale, Andrea , Marchlinski, Francis E , Calkins, Hugh , Sanders, Prashanthan , Packer, Douglas L , Kuck, Karl-Heinz , Onal, Birce , Verma, Atul , DeLurgio, David B. , Investigators, on behalf of the PULSED AF

Circulation | March 6, 2023 | Volume: 147 | Issue: 19 | Pages: 1422-1432

10.1161/circulationaha.123.063988 | PMID 36877118 Get It

Background: Pulsed field ablation uses electrical pulses to cause nonthermal irreversible electroporation and induce cardiac cell death. Pulsed field ablation may have effectiveness comparable to traditional catheter ablation while preventing thermally mediated complications. Methods: The PULSED AF pivotal study (Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF) was a prospective, global, multicenter, nonrandomized, paired single-arm study in which patients with paroxysmal (n=150) or persistent (n=150) symptomatic atrial fibrillation (AF) refractory to class I or III antiarrhythmic drugs were treated with pulsed field ablation. All patients were monitored for 1 year using weekly and symptomatic transtelephonic monitoring; 3-, 6-, and 12-month ECGs; and 6- and 12-month 24-hour Holter monitoring. The primary effectiveness end point was freedom from a composite of acute procedural failure, arrhythmia recurrence, or antiarrhythmic escalation through 12 months, excluding a 3-month blanking period to allow recovery from the procedure. The primary safety end point was freedom from a composite of serious procedure- and device-related adverse events. Kaplan-Meier methods were used to evaluate the primary end points. Results: Pulsed field ablation was shown to be effective at 1 year in 66.2% (95% CI, 57.9 to 73.2) of patients with paroxysmal AF and 55.1% (95% CI, 46.7 to 62.7) of patients with persistent AF. The primary safety end point occurred in 1 patient (0.7%; 95% CI, 0.1 to 4.6) in both the paroxysmal and persistent AF cohorts. Conclusions: PULSED AF demonstrated a low rate of primary safety adverse events (0.7%) and provided effectiveness consistent with established ablation technologies using a novel irreversible electroporation energy to treat patients with AF. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04198701.
Robotics planning in minimally invasive surgery for adult degenerative scoliosis: illustrative case
Pennington, Zach , Brown, Nolan J. , Quadri, Saif S., Pishva, Seyedamirhossein , Kuo, Cathleen C. , Pham, Martin H. , Pennington, Zach

Journal of Neurosurgery: Case Lessons | March 6, 2023 | Volume: 5 | Issue: 10 | Pages: No page available

10.3171/case22520 | PMID 36880510 Get It

BACKGROUND Minimally invasive surgical techniques are changing the landscape in adult spinal deformity (ASD) surgery, enabling surgical correction to be achievable in increasingly medically complex patients. Spinal robotics are one technology that have helped facilitate this. Here the authors present an illustrative case of the utility of robotics planning workflow for minimally invasive correction of ASD. OBSERVATIONS A 60-year-old female presented with persistent and debilitating low back and leg pain limiting her function and quality of life. Standing scoliosis radiographs demonstrated adult degenerative scoliosis (ADS), with a lumbar scoliosis of 53°, a pelvic incidence–lumbar lordosis mismatch of 44°, and pelvic tilt of 39°. Robotics planning software was utilized for preoperative planning of the multiple rod and 4-point pelvic fixation in the posterior construct. LESSONS To the authors’ knowledge, this is the first report detailing the use of spinal robotics for complex 11-level minimally invasive correction of ADS. Although additional experiences adapting spinal robotics to complex spinal deformities are necessary, the present case represents a proof-of-concept demonstrating the feasibility of applying this technology to minimally invasive correction of ASD.
Updates on LI‐RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI
Patel, Richa , Aslam, Anum , Parikh, Neehar D. , Mervak, Benjamin M. , Mubarak, Eman , Higgins, Lily, Lala, Kayli, Conner, Jack F., Khaykin, Valerie , Bashir, Mustafa R. , Gian, Richard Kinh , Burke, Lauren M. , Smith, Elainea N. , Shampain, Kimberly L. , Owen, Dawn , Do, Richard Kinh Gian , Mendiratta-Lala, Mishal , Parikh, Neehar D , Kim, Charles

Journal of Magnetic Resonance Imaging | March 6, 2023 | Volume: 57 | Issue: 6 | Pages: 1641-1654

10.1002/jmri.28659 | PMID 36872608 Get It

As the incidence of hepatocellular carcinoma (HCC) and subsequent treatments with liver‐directed therapies rise, the complexity of assessing lesion response has also increased. The Liver Imaging Reporting and Data Systems (LI‐RADS) treatment response algorithm (LI‐RADS TRA) was created to standardize the assessment of response after locoregional therapy (LRT) on contrast‐enhanced CT or MRI. Originally created based on expert opinion, these guidelines are currently undergoing revision based on emerging evidence. While many studies support the use of LR‐TRA for evaluation of HCC response after thermal ablation and intra‐arterial embolic therapy, data suggest a need for refinements to improve assessment after radiation therapy. In this manuscript, we review expected MR imaging findings after different forms of LRT, clarify how to apply the current LI‐RADS TRA by type of LRT, explore emerging literature on LI‐RADS TRA, and highlight future updates to the algorithm.Evidence Level3.Technical EfficacyStage 2.
Bearing Witness to Joy and Sorrow: Narrative Medicine and Reproductive Endocrinologist and Infertility (REI) Providers’ Journeys in Infertility Treatment
Quinlan, Margaret M. , Carmack, Heather J. , Schambach, Emma

Health Communication | March 6, 2023 | Volume: 39 | Issue: 4 | Pages: 808-817

10.1080/10410236.2023.2185925 | PMID 36872308 Get It

Association of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder Cancer
Murakami, Kaoru , Furuya, Hideki , Hokutan, Kanani , Goodison, Steve , Pagano, Ian , Chen, Runpu , Shen, Cheng‐Huang , Chan, Michael W.Y. , Ng, Chi‐Fai , Kobayashi, Takashi , Miyake, Makito , Thornquist, Mark, Shimizu, Yoshiko, Hayashi, Kazukuni , Rosser, Charles J. , Miyake, Makito , Rosser, Charles J , Furuya, Hideki , Ogawa, Osamu , Wang, Zhangwei, Yu, Kai

International Journal of Molecular Sciences | March 6, 2023 | Volume: 24 | Issue: 5 | Pages: 4943

10.3390/ijms24054943 | PMID 36902377 Get It

Purpose: Bladder cancer (BCa) is one of the most common cancer types worldwide and is characterized by a high rate of recurrence. In previous studies, we and others have described the functional influence of plasminogen activator inhibitor-1 (PAI1) in bladder cancer development. While polymorphisms in PAI1 have been associated with increased risk and worsened prognosis in some cancers, the mutational status of PAI1 in human bladder tumors has not been well defined. Methods: In this study, we evaluated the mutational status of PAI1 in a series of independent cohorts, comprised of a total of 660 subjects. Results: Sequencing analyses identified two clinically relevant 3′ untranslated region (UTR) single nucleotide polymorphisms (SNPs) in PAI1 (rs7242; rs1050813). Somatic SNP rs7242 was present in human BCa cohorts (overall incidence of 72%; 62% in Caucasians and 72% in Asians). In contrast, the overall incidence of germline SNP rs1050813 was 18% (39% in Caucasians and 6% in Asians). Furthermore, Caucasian patients with at least one of the described SNPs had worse recurrence-free survival and overall survival (p = 0.03 and p = 0.03, respectively). In vitro functional studies demonstrated that SNP rs7242 increased the anti-apoptotic effect of PAI1, and SNP rs1050813 was related to a loss of contact inhibition associated with cellular proliferation when compared to wild type. Conclusion: Further investigation of the prevalence and potential downstream influence of these SNPs in bladder cancer is warranted.
Recurrent Esthesioneuroblastoma: Long-Term Outcomes of Salvage Therapy
Ni, Garrett , Iyoha, Ehiremen, Gompel, Jamie J. Van , Link, Michael J. , Peris‐Celda, Maria , Moore, Eric J. , Stokken, Janalee K., Gamez, Mauricio E. , Choby, Garret , Van Gompel, Jamie J , Gamez, Mauricio , Choby, Garret , Pinheiro‐Neto, Carlos

Cancers | March 6, 2023 | Volume: 15 | Issue: 5 | Pages: 1506

10.3390/cancers15051506 | PMID 36900297 Get It

Introduction: Esthesioneuroblastoma (ENB) is a rare malignant neoplasm arising from the olfactory epithelium of the cribriform plate. Although survival is excellent with a reported 5-year overall survival (OS) of 82%, recurrence is frequent and occurs in 40–50% of cases. This study investigates the characteristics of ENB recurrence and the subsequent prognosis of patients with recurrence. Methods: The clinical records of all patients diagnosed as having ENB with subsequent recurrence at a tertiary hospital from 1 January 1960 to 1 January 2020 were retrospectively reviewed. Overall survival (OS) and progression-free survival (PFS) were reported. Results: A total of 64 out of 143 ENB patients had recurrences. In total, 45 out of 64 recurrences met the inclusion criteria and were included in this study. From these, 10 (22%) had a sinonasal recurrence, 14 (31%) had an intracranial recurrence, 15 (33%) had a regional recurrence, and 6 (13%) had a distal recurrence. The average interval from initial treatment to recurrence was 4.74 years. There were no differences in rates of recurrence with respect to age, sex, or types of surgery (endoscopic, transcranial, lateral rhinotomy, and combined). The time to recurrence was shorter for Hyams grades 3 and 4 compared to Hyams grades 1 and 2 (3.75 years vs. 5.70 years, p < 0.05). Patients with recurrence limited to the sinonasal region had a lower overall primary Kadish stage compared to recurrences beyond the sinonasal region (2.60 vs. 3.03, p < 0.05). A total of 9 (20%) out of 45 patients developed secondary recurrence. Following recurrence, the subsequent 5-year OS and PFS were 63 and 56%, respectively. The mean time to secondary recurrence after treatment of the primary recurrence was 32 months, which was significantly shorter than the time to primary recurrence (32 months vs. 57 months, p = 0.048). The mean age of the secondary recurrence group is significantly older than the primary recurrence group (59.78 years vs. 50.31 years, p = 0.02). No statistically significant differences were observed between the secondary recurrence group and the recurrence group in terms of their overall Kadish stages or Hyams grades. Conclusions: Following an ENB recurrence, salvage therapy appears to be an effective therapeutic option with a subsequent 5-year OS of 63%. However, subsequent recurrences are not infrequent and may require additional therapy.
The influence of anatomic stage and receptor status on first recurrence for breast cancer within 5 years (AFT‐01)
Neuman, Heather B. , Schumacher, Jessica R. , Edge, Stephen B. , Ruddy, Kathryn J. , Partridge, Ann H. , Hanlon, Bret M. , Le‐Rademacher, Jennifer , Yang, Dou‐Yan , Havlena, Jeffrey , Greenberg, Caprice C. , Hanlon, Bret M , Le-Rademacher, Jennifer G , Partridge, Ann H , Yu, Menggang , Vanness, David J. , Strand, Carrie

Cancer | March 6, 2023 | Volume: 129 | Issue: 9 | Pages: 1351-1360

10.1002/cncr.34656 | PMID 36872873 Get It

AbstractBackgroundRisk‐stratified follow‐up guidelines that account for the absolute risk and timing of recurrence may improve the quality and efficiency of breast cancer follow‐up. The objective of this study was to assess the relationship of anatomic stage and receptor status with timing of the first recurrence for patients with local‐regional breast cancer and generate risk‐stratified follow‐up recommendations.MethodsThe authors conducted a secondary analysis of 8007 patients with stage I–III breast cancer who enrolled in nine Alliance legacy clinical trials from 1997 to 2013 (ClinicalTrials.gov identifier NCT02171078). Patients who received standard‐of‐care therapy were included. Patients who were missing stage or receptor status were excluded. The primary outcome was days from the earliest treatment start date to the date of first recurrence. The primary explanatory variable was anatomic stage. The analysis was stratified by receptor type. Cox proportional‐hazards regression models produced cumulative probabilities of recurrence. A dynamic programming algorithm approach was used to optimize the timing of follow‐up intervals based on the timing of recurrence events.ResultsThe time to first recurrence varied significantly between receptor types (p < .0001). Within each receptor type, stage influenced the time to recurrence (p < .0001). The risk of recurrence was highest and occurred earliest for estrogen receptor (ER)‐negative/progesterone receptor (PR)‐negative/Her2neu‐negative tumors (stage III; 5‐year probability of recurrence, 45.5%). The risk of recurrence was lower for ER‐positive/PR‐positive/Her2neu‐positive tumors (stage III; 5‐year probability of recurrence, 15.3%), with recurrences distributed over time. Model‐generated follow‐up recommendations by stage and receptor type were created.ConclusionsThis study supports considering both anatomic stage and receptor status in follow‐up recommendations. The implementation of risk‐stratified guidelines based on these data has the potential to improve the quality and efficiency of follow‐up.